Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Prospects for antisense therapy]

T Maekawa1

  • 1Department of Hygiene, Kyoto Prefectural University of Medicine.

[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|May 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Benign epithelial cyst of the spleen with a high production of carbohydrate antigen 19-9.

International surgery·1999
Same author

Xeroderma pigmentosum variant (XP-V) correcting protein from HeLa cells has a thymine dimer bypass DNA polymerase activity.

The EMBO journal·1999
Same author

A patient with a traumatic right diaphragmatic hernia occurring 4 years after sustaining injury--statistical observations of a delayed diaphragmatic hernia caused by uncomplicated injury in Japan.

Nihon geka hokan. Archiv fur japanische Chirurgie·1999
Same author

Mouse ATF-2 null mutants display features of a severe type of meconium aspiration syndrome.

The Journal of biological chemistry·1999
Same author

Translocation and down-regulation of protein kinase C-alpha, -beta, and -gamma isoforms during ischemia-reperfusion in rat brain.

Journal of neurochemistry·1999
Same author

C-myc antisense oligodeoxynucleotides can induce apoptosis and down-regulate Fas expression in rheumatoid synoviocytes.

Arthritis and rheumatism·1999

Antisense oligodeoxynucleotides (AS ODN) offer targeted gene silencing to combat diseases like cancer and viral infections. Modified AS ODN show promise in clinical trials for suppressing disease progression.

Area of Science:

  • Molecular Biology
  • Genetics
  • Pharmacology

Context:

  • Chemotherapy faces challenges due to toxicity from targeting normal and diseased cells.
  • Antisense oligodeoxynucleotides (AS ODN) offer a specific genetic approach to gene expression inhibition.
  • Advances in gene cloning and ODN synthesis facilitate the development of AS therapy.

Purpose:

  • To explore the potential of antisense oligodeoxynucleotides (AS ODN) as a targeted therapeutic strategy.
  • To highlight the development of AS ODN for treating cancer and viral diseases.
  • To discuss the progress and challenges in AS therapy clinical applications.

Summary:

  • AS ODN leverage Watson-Crick base pairing for sequence-specific gene targeting.
  • Chemically modified ODNs, like phosphorothioate analogues, exhibit nuclease resistance and therapeutic potential.

Related Experiment Videos

  • These modified ODNs effectively inhibit oncogene expression and viral replication, suppressing disease cell growth in vitro and in vivo.

    • Impact:

    • AS ODN therapy presents a promising avenue for reducing chemotherapy side effects.
    • Early-phase clinical trials are underway for leukemia and AIDS, evaluating AS ODN toxicity.
    • Despite encountered challenges, AS ODN therapy holds significant potential for future clinical applications.